Introduction
============

Breast cancer is the most common malignancy for women in the United States \[[@b1-crt-2019-210]\]. The incidence rate of breast cancer is reported to increase by 0.4% per year, while the death rate declines annually by 1.6% \[[@b2-crt-2019-210]\]. These data suggest a rapid growing of cancer survivors, leading to the prevalence of multiple primary cancers \[[@b3-crt-2019-210]\]. As is reported, about 4% to 14% of patients diagnosed with breast cancer carry a history of prior cancer \[[@b4-crt-2019-210],[@b5-crt-2019-210]\].

The National Comprehensive Cancer Network believes that being in clinical trials is the best management for patients with cancer \[[@b6-crt-2019-210]\]. However, fewer than 5% of cancer patients can participate in clinical trials due to excessive or overly restrictive exclusion criteria \[[@b7-crt-2019-210],[@b8-crt-2019-210]\], one of which is a history of prior malignancy. For example, more than 80% of lung cancer trials sponsored by the Eastern Cooperative Oncology Group (ECOG) exclude cancer survivors \[[@b9-crt-2019-210]\]. Besides, there are many clinical trials of advanced breast cancer (ABC) excluding patients with prior cancer within the timeframe of 3 years and some exclude patients with prior cancer diagnosed at any time. The practice is largely attributed to the long-held belief that a history of prior cancer may influence the trial conduct and outcomes. While the Food and Drug Administration introduced a draft guidance recently suggesting that patients with a history of prior malignancy should generally be enrolled in clinical trials \[[@b10-crt-2019-210]\]. Similarly, Laccetti et al. \[[@b11-crt-2019-210]\] found that prior cancer did not adversely affect clinical outcomes for lung cancer \[[@b9-crt-2019-210],[@b12-crt-2019-210]\]. However, the prognostic impact of a prior cancer history varies among different cancer types and stage in question \[[@b13-crt-2019-210]\], and the reasonableness of this criterion has not been assessed in patients with ABC.

Therefore, we conducted the study to determine the impact of prior cancers on clinical outcomes among patients with ABC using the Surveillance, Epidemiology, and End Results (SEER) database.

Materials and Methods
=====================

1. Database and case selection
------------------------------

The population-based data were obtained from the SEER Program of the National Cancer Institute, which covers approximately 28% of the U.S. population \[[@b14-crt-2019-210]\]. We selected patients with ABC diagnosed between January 2004 and December 2010 using SEER\*Stat software (ver. 8.3.5, [https:// seer.cancer.gov/seerstat](https://seer.cancer.gov/seerstat)) to ensure a 5-year follow-up at least. Breast cancer was identified by site codes (C50.0-C50.6, C50.8, and C50.9) of the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3). Patients were identified if they had stage IV disease according to the 6th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual. We excluded patients younger than 18 years old at diagnosis, those with incomplete follow-up information including diagnosis dates and survival data, or patients diagnosed at autopsy or via death certificate. Besides, we further excluded patients with a diagnosis of prior breast cancer. Actually, it is challenging to distinguish the primary cancer from recurrent disease when there is a same-site second cancer even in the clinical practice \[[@b11-crt-2019-210]\]. Detailed inclusion and exclusion criteria were included in the online supplementary materials.

A history of primary cancer was derived from the SEER sequence number, which described the sequence of all reportable malignancy over the lifetime of a patient. The sequence number of "00" suggested that the patient had only one primary cancer in the lifetime. For women with multiple primaries, the sequence number of "01" indicated the first cancer and "02" indicated the second one, and so forth. In another word, patients without prior cancer were those whose sequence number were "00" or "01."

2. Variables
------------

Demographic and clinicopathological data were extracted from the SEER database, including age, race, marital status, histology, pathologic grade, status of estrogen receptor (ER) and progesterone receptor (PR), SEER stage, surgery of the primary tumor and chemotherapy. All eligible patients in our study were female. Race/ethnicity was categorized as white, black, Hispanic, and others according to SEER coding manual 2016. Marital status was classified as married, single, separated/widowed/divorced (sep/wid/div) and unknown. According to the SEER terminology, the extent of the disease was described as localized, regional, distant and unstaged. The stage and type of the most recent prior cancer were also recorded in detail. The timing, namely the interval between the diagnosis of prior cancer and index breast cancer, was calculated based on the diagnosis date.

3. Statistical analysis
-----------------------

Pearson chi-square tests were used to analyze categorical variables. The primary outcomes were overall survival (OS) and breast cancer-specific survival (BCSS). Kaplan-Meier method and Gray's test were used to estimate OS and BCSS of no prior cancer vs any prior cancer diagnosis, respectively, before and after propensity score matching (PSM) \[[@b15-crt-2019-210]\]. Survival curves stratified by timing of prior cancer were also constructed based on the Kaplan-Meier method. Both unadjusted and propensity score--adjusted Cox proportional hazards models were built to identify whether the prior cancer history was an independent prognostic factor for OS. To test the impact on BCSS of the prior cancer diagnosis, Fine and Gray's competing risks regression was also performed before and after PSM \[[@b16-crt-2019-210]\]. Since the proportional hazards assumption did not hold based on the Schoenfeld residuals, we included the interactions of covariates with functions of time in the multivariable models \[[@b17-crt-2019-210],[@b18-crt-2019-210]\]. After the introduction of time-dependent covariates, only slight shift of hazard ratios (HR) and the corresponding confidence interval (CI) were observed. A possible explanation for the disproportion might be that it was easy to detect the small departures in a large dataset \[[@b11-crt-2019-210]\]. A two-sided p-value of less than 0.05 indicated statistical significance. All these procedures were conducted in R software (ver. 3.5.1, <http://www.r-project.org>).

4. PSM analysis
---------------

To minimize the baseline confounders, a one-to-one PSM between women with or without a history of prior cancer was carried out using the nearest-neighbor matching method with a caliper distance of 0.2 \[[@b19-crt-2019-210]\]. Variables entered into the PSM algorithm included age, race, marital status, histology, pathologic grade, status of ER and PR, surgery of primary tumor and chemotherapy. After matching, standardized differences were calculated and a value of less than 0.2 denoted meaningful balance \[[@b20-crt-2019-210]\]. Besides, the propensity-score adjusted p-value was provided as well. The PSM procedure and the calculation of standardized differences were performed using R packages of *MatchIt* (ver. 3.0.2), *optmatch* (ver. 0.9-10), and *stddiff* (version 2.0).

5. Ethical statement
--------------------

All analyses of human data conducted in this study were approved by the independent Ethical Committee/Institutional Review Board of Ruijin Hospital and in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was exempted because of the retrospective nature of this study.

Results
=======

In all, 328,092 patients with breast cancer and 14,176 patients with advanced disease were identified, of whom 32,798 (10.0%) and 1,483 (10.5%) carried a history of prior cancer, respectively. After excluding patients with a prior breast cancer diagnosis, a total of 12,126 patients (3.7%) with breast cancer and 466 patients (3.3%) with advanced disease were used for further analysis. We could see that prior cancer was more common among older (\> 64 years old), white and separated/widowed/divorced women. After adjusted for propensity scores, all variables were well-balanced between women with or without prior cancer. An overview of detailed baseline characteristics before and after PSM were provided in [Table 1](#t1-crt-2019-210){ref-type="table"} and [S1 Table](#SD1-crt-2019-210){ref-type="supplementary-material"}.

Type, stage, and timing of the most recent prior malignancy were displayed using treemaps in [Fig. 1](#f1-crt-2019-210){ref-type="fig"}. For women with advanced disease, the most common type included female genital (32.4%), gastrointestinal (23.4%), and respiratory (12.0%) cancers. Most prior cancers were diagnosed at localized (51.7%) or regional (26.0%) stage. The median interval between the diagnosis of prior cancer and the index cancer was 50 months. Most were diagnosed within one year (28.3%), more than 10 years (21.9%) or 5 to 10 years (21.0%) prior to the prior cancer diagnosis in patients with stage IV breast cancer. Similar distribution patterns were observed in patients with breast cancer ([S2 Fig](#SD2-crt-2019-210){ref-type="supplementary-material"}.).

Overall, the Kaplan-Meier plots showed significantly worse prognosis (p \< 0.001) for patients with a history of prior cancer after adjusted for propensity scores, presenting an adverse effect of prior cancer on OS. However, a prior cancer diagnosis was found to be a favorable prognostic factor for BCSS based on the Gray's test (pBCSS \< 0.001) for some uncovered reasons ([Fig. 2](#f2-crt-2019-210){ref-type="fig"}). Both the unfavorable impact on OS (p \< 0.001) and the favorable impact on BCSS (pBCSS=0.005) were reaffirmed in the unadjusted survival curves ([S3 Fig](#SD3-crt-2019-210){ref-type="supplementary-material"}.).

[Fig. 3](#f3-crt-2019-210){ref-type="fig"} demonstrated the impact of timing of prior cancer diagnosis on OS and we found that patients who had a prior cancer diagnosis with a disease-free interval of 4 years or longer showed a similar survival to those without prior cancer (HR, 1.16; 95% CI, 0.98 to 1.37; p=0.074). Besides, we found that prior cancers from endocrine system (HR, 0.89; 95% CI, 0.56 to 1.42; p=0.630) or head and neck (HR, 1.24; 95% CI, 0.54 to 2.83; p=0.618) and prior cancers at **in situ** (HR, 1.02; 95% CI, 0.48 to 2.18; p=0.962) or localized (HR, 1.15; 95% CI, 0.97 to 1.36; p=0.083) stage might not influence the prognosis significantly. Patients with different timing, stage or type of prior cancer diagnosis presented non-inferior or even slightly superior BCSS to those without prior cancer. Detailed data were presented in [Table 2](#t2-crt-2019-210){ref-type="table"}.

After adjusted for age, race, marital status, grade, status of ER and PR, and the treatment modality, a history of prior cancer were found to be an independent prognostic factor for overall (HR, 1.23; 95% CI, 1.07 to 1.41; p=0.004) and breast cancer-specific (subdistribution hazard ratio \[SHR\], 0.75; 95% CI, 0.63 to 0.88; p \< 0.001) survival with the opposite direction in the propensity score-adjusted models ([Table 3](#t3-crt-2019-210){ref-type="table"}). The association remained significant both in the Cox model (HR, 1.18; 95% CI, 1.07 to 1.30; p=0.001) and the competing risks model before PSM (SHR, 0.64; 95% CI, 0.56 to 0.74; p \< 0.001) ([S4 Table](#SD4-crt-2019-210){ref-type="supplementary-material"}).

###### 

Comparison of overall survival between patients with and without prior cancer. (A-J) The comparisons with different referenced timeframe (1 to 10 years) being adopted. The blue curves represent the patients without prior cancer; the red ones represent the patients with prior cancer diagnosed outside the referenced timeframe; the green ones represent the patients with prior cancer diagnosed inside the referenced timeframe. p~T~ (p~Total~) denotes the log-rank test for the total three curves; p~O~ (p~Outside~) denotes the log-rank test between the red and blue curves; p~I~ (p~Inside~) denotes the log-rank test between the green and blue curves.

Discussion
==========

This study focused on the impact of a prior cancer diagnosis on clinical outcomes among patients with stage IV breast cancer. First, approximately 10% of patients were diagnosed with a history of prior cancer and 3% had a history of different-site prior malignancy. Second, more than half prior cancers were diagnosed at *in situ* orlocalized stage. Furthermore, a prior cancer history was observed to impact overall and cancer-specific survival in the opposite direction. While no survival detriment was observed in patients with prior malignancies at *in situ* or localized stage or those diagnosed outside the timeframe of 4 years.

Over the past decades, survival for stage IV breast cancer has been improving steadily and about one-third of women with advanced disease live more than 5 years \[[@b2-crt-2019-210],[@b21-crt-2019-210]\]. Consistent with the findings reported herein, approximately 7% to 14% of patients with breast cancer were reported to have a history of prior breast cancer and about 4% to 8% of patients had a prior cancer on different sites in a previous study \[[@b4-crt-2019-210]\]. Besides, patients older than 64 years old were most commonly diagnosed with a history of prior cancer in the present study. Similar findings were also reported by Murphy et al. \[[@b4-crt-2019-210]\] and Bluethmann et al. \[[@b22-crt-2019-210]\]. The rapid growing of cancer survivors urges us to revisit the longstanding practice of excluding a majority of otherwise eligible patients with a history of prior cancer from clinical trials, especially the older patients, the very population with complex healthcare needs. As is stated, the widely adopted exclusion criterion may further limit the generalizability and slow the accrual in view of the significant barriers of participation in clinical trials \[[@b4-crt-2019-210],[@b5-crt-2019-210],[@b9-crt-2019-210]\]. And the plea to liberalize the exclusion criteria about a history of previous malignancy has been made by several working groups \[[@b8-crt-2019-210],[@b10-crt-2019-210],[@b23-crt-2019-210]\]. Accordingly, the current study was performed to assess the feasibility of enrolling patients with prior malignancy into clinical trials.

Arguments against the enrollment of patients with previous malignancy mainly centered on the concern that the inherently vulnerable patients may present worse survival outcomes and more serious adverse events and thus, jeopardize the development of a new drug. Consequently, understanding the impact of prior malignancy is of clinical importance. Several studies have reported detailed results for specific sites of the index cancer, including lung cancer, prostate cancer and gastrointestinal cancer \[[@b9-crt-2019-210],[@b11-crt-2019-210],[@b12-crt-2019-210],[@b24-crt-2019-210],[@b25-crt-2019-210]\]. Still, there is no study demonstrating the impact of the prior cancer for patients with ABC. In this retrospective study, we found that history of prior cancer might impair the survival of women with advanced disease in the overall population. After adjustment for propensity scores, these patients had approximately a quarter increased risks of mortality. On the contrary, a pan-cancer study by Zhou et al. \[[@b5-crt-2019-210]\] reported that pati-ents with stage IV breast cancer who carried a history of previous malignancy showed similar OS to those without a prior cancer (p=0.48). The discrepancy could be attributed to the different selection criteria. Our study excluded patients with a prior breast cancer diagnosis, which usually presented a more favorable prognosis when compared to other prior cancer types \[[@b1-crt-2019-210]\].

In the subgroup analysis, a previous malignancy at *in situ* or localized stage did not affect the survival adversely. In the current study, prior malignancy diagnosed at *in situ* or localized stage made up 53.6% of the overall population, suggesting that a substantial proportion of patients with advanced disease who carried a prior cancer history might be considered for enrollment into clinical trials. A possible explanation might be that the early-stage prior cancer presented less invasive tumor biology when compared to the advanced breast cancer and thus, less prior cancer-related mortality would be observed. Consistently, a study by Schonberg et al. \[[@b26-crt-2019-210]\] showed that women age 67 years or older diagnosed with ductal carcinoma *in situ* or stage I breast cancer presented a slightly better survival than their matched controls without a diagnosis of breast cancer. As is reported, higher 5-year relative survival rates are observed for localized genital, digestive, respiratory or urinary cancer when compared to ABC \[[@b1-crt-2019-210]\]. Hence, it may be speculated that patients with aggressive disease would not suffer significant detriment to survival from an earlier-stage prior cancer with low invasiveness. Furthermore, cancers at early stage usually response better to local and systemic treatment \[[@b11-crt-2019-210]\]. Given the early diagnosis, indolent nature, and the great treatment response, it seems reasonable that patients with early-stage prior cancers may present a favorable prognosis.

The time elapsed between the diagnosis of prior cancer and index breast cancer are a factor of great importance when assessing the effect of prior cancer \[[@b5-crt-2019-210]\]. In order to find the optimal time window, we performed survival analysis comparing OS between patients without a prior cancer history and those with prior cancer diagnosed outside the referenced timeframe. Finally, descending HRs were observed with the ascending diagnosis interval and we found that patients with a previous malignancy diagnosed four years or longer before the breast cancer showed similar survival to those without previous malignancy diagnosis. As is reported, notable decline is observed in deaths or relapse occurred in years 5-10 when compared to years 1-5 among the aggressive epithelial cancers such as ovarian cancer, gastric cancer and lung cancer \[[@b27-crt-2019-210]-[@b29-crt-2019-210]\]. Consequently, we presume it that there is a time point beyond which the prior cancer may be considered cured to some extent if no relapse or progression observed, accounting for no survival detriment from prior cancer diagnosed outside the timeframe of four years. In our study, more than half of the prior malignancy occurred four years or longer before the breast cancer diagnosis, indicating that a specific subgroup of patients with prior cancer history was eligible for breast cancer trials.

Also, our study revealed that type of previous malignancy may affect both OS and BCSS significantly. From our perspective, the OS of patients with prior cancer is determined by the cancer with more aggressive biology between prior cancer and index cancer. As is reported by Zhou et al. \[[@b5-crt-2019-210]\], cancers with relatively good prognoses are more inclined to be affected by prior malignancy, whereas the outcomes of aggressive cancers are usually completely unrelated to prior cancer. Our work revealed that prior cancers of digestive, respiratory, genital, and urinary system had an adverse effect on the prognosis for ABC patients. According to Cancer Statistics 2018, breast cancer presents more favorable prognosis than these cancers listed above \[[@b1-crt-2019-210]\]. This may be the reason why different cancer types have different effects on OS.

As is expected, a previous malignancy diagnosis was associated with significantly higher prior cancer-related mortality, leading to the worse OS of those patients. However, better BCSS in the overall population was observed for those with prior malignancy for some uncovered reasons when using the propensity scores-adjusted competing risks regression. Analogous results were presented in each subgroup. One possible explanation is that prior cancer-specific mortality is a competing event to breast cancer-specific mortality. According to Cancer Statistics 2018, female breast cancer is one of the cancers with the highest survival when comparing with cancers from female genitourinary, gastrointestinal, or respiratory systems, which account for the majority of the prior cancers in our study \[[@b1-crt-2019-210]\]. Accordingly, the growing in prior cancer-related mortality (events of competing risks) leads to the decline in breast cancer-specific mortality (events of interest). Another potential explanation is the lead-time bias \[[@b11-crt-2019-210]\]. Patients diagnosed with prior cancer might seek routine medical attention to the prior cancer, allowing for early diagnosis in the disease course \[[@b26-crt-2019-210]\]. This explanation echoed the previous study by Ahn et al. \[[@b30-crt-2019-210]\] that increased comorbidity burden is associated with earlier cancer diagnosis. In terms of treatment, some regimens for systemic therapy used in gastrointestinal or respiratory cancers may also work in ABC. In spite of these speculations, the relatively better prognosis of breast cancer along with the competing relationship between breast cancer-specific mortality and prior cancer-related mortality may be the main reasons and work together leading to the lower OS and higher BCSS for patients with previous malignancy. Still, further investigation is required.

Another reason for excluding prior cancer from breast cancer trials is that preexposure to the prior cancer treatment may interfere with the trial outcomes, such as the efficacy and adverse events profiles. However, it is hard to address the issue in our study due to the limited data in the SEER database.

Still, there are several limitations of our work. First, some variables were not available in the SEER database, such as the comorbidities. So it is difficult to match the comorbidities and other unobserved confounding factors in the PSM analyses. Any hidden bias owing to latent variables remained after matching. Neither did we include these variables into the multivariable regression model. Second, SEER did not provide detailed information on treatment, making the adjustment impossible for both locoregional and systemic treatment. In addition, after excluding patients with a prior breast cancer diagnosis, a small sample size of patients with previous malignancy were identified and thereby, limited the generalizability to those with second primary breast cancer. Further investigation is required. Furthermore, as is stated above, we could not address the issue of the efficacy and adverse events profiles of prior cancer treatment.

In conclusion, a substantial proportion of patients with stage IV breast cancer have a history of prior malignancy. More than half of these cases are diagnosed at *in situ* or localized stage outside the timeframe of 4 years. These patients may be considered for enrollment in clinical trials of ABC since no survival detriment was observed. It also suggests a broader inclusion criterion and emphasizes the importance that exclusion criteria should be modified based on specific stage, type and timing of prior cancer rather than being duplicated from prior trials. Only in this way can patients with a history of prior cancer get access to the stateof-the-art therapies.
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Baseline characteristics of patients diagnosed with advanced with advanced breast cancer after propensity score matching

###### 

Type, stage and time distribution of the most recent prior malignancy for patients with breast cancer.

###### 

Overall (A) and breast cancer-specific (B) survival for patients with or withour prior cancer diagnosis before propensity score matching. Two-sided p-values were estimated and compared based on the log-lank test (A) and Gray\'s test (B)

###### 

Multivariable analysis of overall and breast cancer-specific survival among patiens with prior cancer before propensity score matching.

![Type, stage, and time distribution of the most recent prior malignancy for patients with advanced breast cancer.](crt-2019-210f1){#f1-crt-2019-210}

![Overall (A) and breast cancer-specific (B) survival (BCSS) for patients with or without prior cancer diagnosis after propensity score matching. Two-sided p-values were estimated and compared based on the log-rank test (A) and Gray's test (B).](crt-2019-210f2){#f2-crt-2019-210}

###### 

Baseline characteristics of patients diagnosed with advanced breast cancer before propensity score matching

  Characteristic                                                      Total    Prior malignancy   No prior malignancy   p-value
  ------------------------------------------------------------------- -------- ------------------ --------------------- ----------
  **Age (yr)**                                                                                                          
   \< 40                                                              969      5 (1.1)            964 (7.1)             \< 0.001
   40-64                                                              7,493    177 (38.0)         7,316 (54.2)          
   \> 64                                                              5,492    284 (60.9)         5,208 (38.6)          
  **Race**                                                                                                              
   White                                                              9,269    348 (74.7)         8,921 (66.1)          0.001
   Black                                                              2,300    55 (11.8)          2,245 (16.6)          
   Hispanic                                                           1,395    33 (7.1)           1,362 (10.1)          
   Other                                                              990      30 (6.4)           960 (7.1)             
  **Marital status**                                                                                                    
   Married                                                            6,041    189 (40.6)         5,852 (43.4)          \< 0.001
   Single                                                             2,791    56 (12.0)          2,735 (20.3)          
   Sep/wid/div                                                        4,517    201 (43.1)         4,316 (32.0)          
   Unknown                                                            605      20 (4.3)           585 (4.3)             
  **Histology**                                                                                                         
   IDC                                                                10,561   356 (76.4)         10,205 (75.7)         0.001
   ILC                                                                1,657    73 (15.7)          1,584 (11.7)          
   Other                                                              1,699    37 (7.9)           1,699 (12.6)          
  **Grade**                                                                                                             
   G1                                                                 841      32 (6.9)           809 (6.0)             0.840
   G2                                                                 4,643    158 (33.9)         4,485 (33.3)          
   G3/G4                                                              6,247    202 (43.3)         6,045 (44.8)          
   Unknown                                                            2,223    74 (15.9)          2,149 (15.9)          
  **ER**                                                                                                                
   Positive                                                           9,245    284 (60.9)         8,961 (66.4)          0.001
   Negative                                                           3,617    126 (27.0)         3,491 (25.9)          
   Unknown                                                            1,092    56 (12.0)          1,036 (7.7)           
  **PR**                                                                                                                
   Positive                                                           7,228    214 (45.9)         7,014 (52.0)          0.001
   Negative                                                           5,540    193 (41.4)         5,347 (39.6)          
   Unknown                                                            1,186    59 (12.7)          1,127 (8.4)           
  **Treatment**                                                                                                         
   No                                                                 4,016    177 (38.0)         3,839 (28.5)          \< 0.001
   Surg only                                                          2,192    95 (20.4)          2,097 (15.5)          
   Chemo only                                                         3,822    99 (21.2)          3,723 (27.6)          
   Surg and Chemo                                                     3,924    95 (20.4)          3,829 (28.4)          
  **Cause of death^[a)](#tfn1-crt-2019-210){ref-type="table-fn"}^**                                                     
   Alive                                                              2,287    46 (9.9)           2,241 (16.6)          \< 0.001
   Breast cancer specific                                             10,040   279 (59.9)         9,761 (72.4)          
   All other sites                                                    1,627    141 (30.3)         1,486 (11.0)          
   Total                                                              13,954   466                13,488                

Values are presented as number (%). Sep/wid/div, separated/widowed/divorced; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; Surg, surgery; Chemo, chemotherapy.

Dependent variable, no necessary to calculate the standardized difference.

###### 

Association of timing, stage, and type of prior cancer with overall and breast cancer-specific survival

  Variable                                                                                     Overall survival   Breast cancer-specific survival                                           
  -------------------------------------------------------------------------------------------- ------------------ --------------------------------- ---------- --------- ------------------ ----------
  **Part I: Prior cancer diagnosed outside the referenced time frame (vs. no prior cancer)**                                                                                                
   1 Yr                                                                                        124/132            1.21 (1.04-1.40)                  0.015      59/132    0.93 (0.79-1.10)   0.396
   2 Yr                                                                                        162/173            1.18 (1.01-1.38)                  0.036      84/173    0.94 (0.79-1.12)   0.512
   3 Yr                                                                                        190/205            1.19 (1.01-1.39)                  0.038      104/205   0.96 (0.80-1.16)   0.694
   4 Yr                                                                                        213/231            1.16 (0.98-1.37)                  0.074      119/231   0.98 (0.81-1.18)   0.836
   5 Yr                                                                                        243/266            1.16 (0.98-1.38)                  0.080      140/266   1.01 (0.84-1.23)   0.887
   6 Yr                                                                                        268/295            1.18 (0.99-1.41)                  0.072      156/295   1.09 (0.89-1.33)   0.427
   7 Yr                                                                                        289/317            1.14 (0.94-1.38)                  0.171      170/317   1.13 (0.92-1.39)   0.275
   8 Yr                                                                                        302/330            1.14 (0.93-1.40)                  0.202      181/330   1.11 (0.89-1.39)   0.347
   9 Yr                                                                                        324/355            1.12 (0.90-1.40)                  0.308      201/355   1.06 (0.83-1.36)   0.639
   10 Yr                                                                                       333/364            1.08 (0.85-1.36)                  0.533      210/364   0.99 (0.76-1.28)   0.928
  **Part II: Prior cancer stage (vs. no prior cancer)**                                                                                                                                     
   *In situ*                                                                                   7/9                1.02 (0.48-2.18)                  0.962      7/9       1.41 (0.68-2.90)   0.353
   Localized                                                                                   215/241            1.15 (0.97-1.36)                  0.083      172/241   1.06 (0.89-1.27)   0.516
   Regional                                                                                    109/121            1.32 (1.07-1.64)                  0.010      60/121    0.61 (0.46-0.80)   \< 0.001
   Distant                                                                                     70/73              1.84 (1.40-2.42)                  \< 0.001   27/73     0.40 (0.27-0.60)   \< 0.001
   Unstaged                                                                                    19/22              1.34 (0.85-2.13)                  0.210      13/22     0.86 (0.49-1.50)   0.587
  **Part III: Prior cancer type (vs. no prior cancer)**                                                                                                                                     
   Digestive                                                                                   99/109             1.29 (1.03-1.61)                  0.025      61/109    0.71 (0.54-0.93)   0.013
   Head and neck                                                                               7/8                1.24 (0.54-2.83)                  0.618      4/8       0.63 (0.22-1.77)   0.379
   Respiratory                                                                                 53/56              2.08 (1.50-2.87)                  \< 0.001   25/56     0.58 (0.37-0.91)   0.017
   Genital                                                                                     140/151            1.29 (1.07-1.55)                  0.007      97/151    0.86 (0.69-1.08)   0.194
   Urinary                                                                                     48/52              1.64 (1.22-2.21)                  0.001      29/52     0.75 (0.51-1.11)   0.151
   Endocrine                                                                                   23/31              0.89 (0.56-1.42)                  0.630      21/31     1.05 (0.67-1.66)   0.819
   Other                                                                                       50/59              0.99 (0.76-1.29)                  0.958      42/59     1.00 (0.75-1.34)   0.996

HR, hazard ratio; CI, confidence interval; SHR, subdistribution hazard ratio.

###### 

Propensity score-adjusted multivariable analysis of overall and breast cancer-specific survival among patients with prior cancer

                             HR (95% CI)        p-value    Breast cancer-specific SHR (95% CI)   Breast cancer-specific p-value
  -------------------------- ------------------ ---------- ------------------------------------- --------------------------------
  **Prior cancer history**                                                                       
   No                        Reference          \-         Reference                             \-
   Yes                       1.23 (1.07-1.41)   0.004      0.75 (0.63-0.88)                      \< 0.001
  **Age (yr)**                                                                                   
   \< 40                     Reference          \-         \-                                    \-
   40-64                     1.14 (0.53-2.45)   0.737      \-                                    \-
   \> 64                     1.55 (0.72-3.35)   0.262      \-                                    \-
  **Marital status**                                                                             
   Married                   Reference          \-         Reference                             \-
   Single                    1.01 (0.80-1.28)   0.914      1.01 (0.78-1.31)                      0.950
   Sep/wid/div               1.24 (1.06-1.45)   0.009      1.22 (1.02-1.47)                      0.031
   Unknown                   0.96 (0.67-1.36)   0.815      0.87 (0.56-1.36)                      0.544
  **Grade**                                                                                      
   G1                        Reference          \-         Reference                             \-
   G2                        1.37 (1.01-1.87)   0.046      1.42 (1.00-2.00)                      0.048
   G3/G4                     1.62 (1.19-2.21)   0.002      1.53 (1.09-2.17)                      0.015
   Unknown                   1.33 (0.95-1.87)   0.092      1.13 (0.77-1.66)                      0.539
  **ER**                                                                                         
   Positive                  Reference          \-         \-                                    \-
   Negative                  1.40 (1.11-1.75)   0.004      \-                                    \-
   Unknown                   1.64 (0.81-3.30)   0.167      \-                                    \-
  **PR**                                                                                         
   Positive                  Reference          \-         Reference                             \-
   Negative                  1.39 (1.13-1.70)   0.002      1.20 (1.00-1.44)                      0.054
   Unknown                   1.16 (0.59-2.27)   0.670      1.30 (0.98-1.44)                      0.066
  **Treatment**                                                                                  
   No                        Reference          \-         Reference                             \-
   Surg only                 0.63 (0.44-0.65)   \< 0.001   0.54 (0.42-0.69)                      \< 0.001
   Chemo only                0.68 (0.56-0.83)   \< 0.001   0.95 (0.76-1.18)                      0.614
   Surg and chemo            0.31 (0.25-0.39)   \< 0.001   0.58 (0.46-0.73)                      \< 0.001

HR, hazard ratio; CI, confidence interval; SHR, subdistribution hazard ratio; Sep/wid/div, separated/widowed/divorced; ER, estrogen receptor; PR, progesterone receptor; Surg, surgery; Chemo, chemotherapy.

[^1]: Caijin Lin and Jiayi Wu contributed equally to this work.
